The metabolic reprogramming in tumor cells by oncogenes, like RAS and, in particular, the mutant KRAS, supports the uncontrolled tumor growth, promotes the Warburg effect and affects the glutamine/lipid metabolism, thereby mediating the therapy resistance [48]. Here, KRAS is linked to neoplasm.